Figure 1.
Study design of the ECHELON-2 trial. ∗Targeting 75% (±5%) ALCL per European Union and Canadian regulatory commitment. AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; EATL, enteropathy-associated T-cell lymphoma; HSTCL, hepatosplenic T-cell lymphoma; IPI, International Prognostic Index; PTCL-NOS, PTCL, not otherwise specified; q3w, every 3 weeks; R, randomized.

Study design of the ECHELON-2 trial. ∗Targeting 75% (±5%) ALCL per European Union and Canadian regulatory commitment. AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; EATL, enteropathy-associated T-cell lymphoma; HSTCL, hepatosplenic T-cell lymphoma; IPI, International Prognostic Index; PTCL-NOS, PTCL, not otherwise specified; q3w, every 3 weeks; R, randomized.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal